These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
627 related articles for article (PubMed ID: 28527613)
1. No. 344-Opportunistic Salpingectomy and Other Methods of Risk Reduction for Ovarian/Fallopian Tube/Peritoneal Cancer in the General Population. Salvador S; Scott S; Francis JA; Agrawal A; Giede C J Obstet Gynaecol Can; 2017 Jun; 39(6):480-493. PubMed ID: 28527613 [TBL] [Abstract][Full Text] [Related]
2. Guideline No. 403: Initial Investigation and Management of Adnexal Masses. Salvador S; Scott S; Glanc P; Eiriksson L; Jang JH; Sebastianelli A; Dean E J Obstet Gynaecol Can; 2020 Aug; 42(8):1021-1029.e3. PubMed ID: 32736853 [TBL] [Abstract][Full Text] [Related]
3. No. 370-Management of Squamous Cell Cancer of the Vulva. Francis JA; Eiriksson L; Dean E; Sebastianelli A; Bahoric B; Salvador S J Obstet Gynaecol Can; 2019 Jan; 41(1):89-101. PubMed ID: 30580832 [TBL] [Abstract][Full Text] [Related]
5. Guideline No. 390-Classification and Management of Endometrial Hyperplasia. Auclair MH; Yong PJ; Salvador S; Thurston J; Colgan TTJ; Sebastianelli A J Obstet Gynaecol Can; 2019 Dec; 41(12):1789-1800. PubMed ID: 31785798 [TBL] [Abstract][Full Text] [Related]
6. Guideline No. 408: Management of Gestational Trophoblastic Diseases. Eiriksson L; Dean E; Sebastianelli A; Salvador S; Comeau R; Jang JH; Bouchard-Fortier G; Osborne R; Sauthier P J Obstet Gynaecol Can; 2021 Jan; 43(1):91-105.e1. PubMed ID: 33384141 [TBL] [Abstract][Full Text] [Related]
7. No. 366-Gynaecologic Management of Hereditary Breast and Ovarian Cancer. Jacobson M; Bernardini M; Sobel ML; Kim RH; McCuaig J; Allen L J Obstet Gynaecol Can; 2018 Nov; 40(11):1497-1510. PubMed ID: 30473125 [TBL] [Abstract][Full Text] [Related]
8. The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift. Reade CJ; McVey RM; Tone AA; Finlayson SJ; McAlpine JN; Fung-Kee-Fung M; Ferguson SE J Obstet Gynaecol Can; 2014 Feb; 36(2):133-140. PubMed ID: 24518912 [TBL] [Abstract][Full Text] [Related]
9. Extending the safety evidence for opportunistic salpingectomy in prevention of ovarian cancer: a cohort study from British Columbia, Canada. Hanley GE; Kwon JS; Finlayson SJ; Huntsman DG; Miller D; McAlpine JN Am J Obstet Gynecol; 2018 Aug; 219(2):172.e1-172.e8. PubMed ID: 29852159 [TBL] [Abstract][Full Text] [Related]
10. Hysterectomy with opportunistic salpingectomy versus hysterectomy alone. van Lieshout LAM; Steenbeek MP; De Hullu JA; Vos MC; Houterman S; Wilkinson J; Piek JM Cochrane Database Syst Rev; 2019 Aug; 8(8):CD012858. PubMed ID: 31456223 [TBL] [Abstract][Full Text] [Related]
11. Examining indicators of early menopause following opportunistic salpingectomy: a cohort study from British Columbia, Canada. Hanley GE; Kwon JS; McAlpine JN; Huntsman DG; Finlayson SJ; Miller D Am J Obstet Gynecol; 2020 Aug; 223(2):221.e1-221.e11. PubMed ID: 32067967 [TBL] [Abstract][Full Text] [Related]
12. Incidental nonuterine high-grade serous carcinomas arise in the fallopian tube in most cases: further evidence for the tubal origin of high-grade serous carcinomas. Gilks CB; Irving J; Köbel M; Lee C; Singh N; Wilkinson N; McCluggage WG Am J Surg Pathol; 2015 Mar; 39(3):357-64. PubMed ID: 25517954 [TBL] [Abstract][Full Text] [Related]
13. The impact of opportunistic salpingectomy on ovarian cancer mortality and healthcare costs: a call for universal insurance coverage. Naumann RW; Hughes BN; Brown J; Drury LK; Herzog TJ Am J Obstet Gynecol; 2021 Oct; 225(4):397.e1-397.e6. PubMed ID: 33798477 [TBL] [Abstract][Full Text] [Related]
14. Beyond Sterilization: A Comprehensive Review on the Safety and Efficacy of Opportunistic Salpingectomy as a Preventative Strategy for Ovarian Cancer. Zadabedini Masouleh T; Etchegary H; Hodgkinson K; Wilson BJ; Dawson L Curr Oncol; 2023 Nov; 30(12):10152-10165. PubMed ID: 38132373 [TBL] [Abstract][Full Text] [Related]
15. Opportunistic Salpingectomy at the Time of Urogynecologic Surgery: Why, in Whom, and How? Catanzarite T; Eskander RN Female Pelvic Med Reconstr Surg; 2020 Jun; 26(6):401-406. PubMed ID: 31135579 [TBL] [Abstract][Full Text] [Related]
16. No. 351-Transvaginal Mesh Procedures for Pelvic Organ Prolapse. Larouche M; Geoffrion R; Walter JE J Obstet Gynaecol Can; 2017 Nov; 39(11):1085-1097. PubMed ID: 29080723 [TBL] [Abstract][Full Text] [Related]
17. Prophylactic salpingectomy for the prevention of ovarian cancer: Who should we target? Kotsopoulos J; Narod SA Int J Cancer; 2020 Sep; 147(5):1245-1251. PubMed ID: 32037528 [TBL] [Abstract][Full Text] [Related]
18. Primary prevention of ovarian cancer: a patient decision aid for opportunistic salpingectomy. van Lieshout LAM; Gelderblom ME; de Hullu JA; The R; van Ginkel AA; Oerlemans AJM; Smeets KMWH; Schreurs MPH; Piek JMJ; Hermens RPMG Am J Obstet Gynecol; 2022 Feb; 226(2):234.e1-234.e14. PubMed ID: 34536392 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of opportunistic salpingectomy vs tubal ligation at the time of cesarean delivery. Venkatesh KK; Clark LH; Stamilio DM Am J Obstet Gynecol; 2019 Jan; 220(1):106.e1-106.e10. PubMed ID: 30170036 [TBL] [Abstract][Full Text] [Related]